The interesting part is some new terminology in the Report under...

The interesting part is some new terminology in the Report under Outlook :
."..expand our cancer diagnostics portfolio through acquisition or in-licensing of complementary diagnosticassets for unmet needs in early detection, diagnosis and monitoring of cancer that..."

"The Company’s commercialisation strategy is to partner with certified laboratories to initially launch the BARD1 autoantibodytests as Laboratory Developed Tests (LDTs) in Australia and the USA to commence commercialisation and real-world productacceptance. If successful, the Company then plans to seek to partner with leading diagnostic distributors to develop andregister In Vitro Diagnostic (IVD) kits with the US FDA, Australian TGA and gain European CE-IVD marking to drive geographicexpansion, clinical adoption, market acceptance and access."

Two terms that are new to me and I've been on board for a while:

In-licencing? explained here: https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/what-is-in-licensing/

IVD?
"In vitro diagnostic tests are used for in vitro examination of specimens derived from the human body to provide information for screening, diagnosis, or treatment monitoring purposes. An IVD test may include reagents provided either in kit format or separately, as well as calibrators, and controls." sourced from WHO.

Good luck interpreting that.
R.